The Joint Health Challenge
Joint health is a broad term, meaning different things to different people. However, one thing is certain; a majority of people are concerned about their joint health as they age. Joint discomfort is not limited to the older demographic. Modern lifestyles challenge joint comfort for all ages with various exercise regimes, sports participation and the common aches and pains we all deal with to varying degrees.
The FlexPro MD® Advantage
The exclusive, patented formula of FlexPro MD® addresses the key factors involved in maintaining joint health. A blend of Phospholipid-bound Omega-3 Fatty Acids, Zanthin® Natural Astaxanthin, and proprietary Flexuron™ Hyaluronic Acid is clinically proven to attenuate joint discomfort in as little as 7-14 days (as evidenced by WOMAC and VAS scores).
FlexPro MD® is clinically proven to be 3 times more effective than the current supplement standard of care, glucosamine/chondroitin. The FlexPro MD® clinically effective dose comes in a single, small softgel. Additionally, FlexPro MD® adds no salts to the users’ diet. Compared to the large doses recommended for glucosamine/chondroitin therapy, which come in large pills and deliver additional salts.
FlexPro MD®, based on a peer-reviewed published mechanistic study, was shown to be as effective as a leading NSAID.
Valensa’s Three-Pronged Approach
FlexPro MD® formula contains Zanthin® Natural Astaxanthin. The powerful antioxidant capabilities of natural astaxanthin are quite useful for maintenance of good joint health and relief of joint discomfort. It is well known that reactive oxygen species can cause inflammation in human tissues. Reactive oxygen species are a necessary part of human biology, but often there is too much, which becomes deleterious. Astaxanthin is known to clear excessive reactive oxygen species (ROS) as well as lower TNF-alpha and COX2 marker expressions.
FlexPro MD® formula contains a sustainable source, phospholipid-bound, DHA/EPA Omega-3 rich supplement. Phospholipids are the most efficient way to deliver omega-3 fatty acids into the body as well as being the building blocks of cell membranes. It is well known that omega-3 fatty acids play an important role in reducing inflammation markers and protecting membranes. Our joints, just like every part of our body, are constantly regenerating, rebuilding. Phospholipid-bound Omega-3 Fatty Acids provide the tools our bodies need to efficiently complete that process.
FlexPro MD® formula contains Flexuron®, a proprietary form of hyaluronic acid. Hyaluronic acid is present in synovial fluid, cartilage and connective tissue; all of which are present in synovial joints. Hyaluronic acid nourishes the synovial fluid within the joints. Extensive clinical evidence suggests that hyaluronic acid, taken orally, can mediate joint discomfort and is absorbed by the body.
The Valensa Advantage is one of quality and traceability. The Valensa team is comprised of skilled farmers, engineers and scientists. Vertical integration provides traceability, our GMP extraction facility (regulated by the FDA) provides peace of mind, and our investments in on-site quality control and quality assurance systems goes above and beyond. Our customers are welcome here, you will be impressed!
FlexPro MD® Clinical Trial Results
Percentage of Pain-Free Subjects based on WOMAC Test
Percentage of Pain-Free Subjects based on VAS Self-Evaluation
The Valensa Advantage
|Industry Concerns||Valensa Solutions|
|Large Pill||Small Pill, Easy to Swallow|
|Commodity||Clinical Trial Formulation Intellectual Property Protection|
|Need for Multiple Benefits||Joint Care + Cardio Benefit|
|Efficacy||Fast Acting, Works in 7-14 days|
|Safety||Valensa On-Site QA, Valensa On-Site QC|
|Purity||Marine Stewardship Council (MSC) Compliance – ECO-HARVESTING®|
|Salt Load||No Salts|
|Joint Care||US 8,481,072 | US 8,557,275 | US 8,524,980 | US 8,507,757 | US 8,962,924 | US 8,999,373 | US 9,034,366 | US – 1 in Allowance | US – 3 Pending | DE – 3 Issued | EP & KR Pending||FlexPro MD®|
|Joint Care||DE – Issued | US – Pending | EP – Pending||FlexPro ES|
|Eye Health||DE – 2 Issued | KR – Issued | EP – Pending||EyePro MD|
|Cardiovascular||US 8,663,704 | US 8,728,531 | IN – Pending||Deep Ocean Krill®|
|Cellular Health||AU, DE, KR IssuedAU, DE, KR Issued||Spiruzan™|
- Saw Palmetto Adulteration Found in Six Suppliers
- Valensa International Gets US Patent for Eye Health Formula
- E.I.D Parry’s Microalgae Facility Successfully Completes U.S. FDA Inspection, Paves Way for New Products
- Parry Organic Spirulina Achieves ‘Certified Raw’ and ‘Certified Clean’ Status
- Valensa Launches Chia Gold® Stabilized Chia Seed Oil in EU after Novel Foods Approval
- Valensa To Commercialize Algal Scientific Algae-Based Immune Health Ingredients in U.S. Human Health & Nutrition Markets